Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420732 · ClinicalTrials.gov registry record · Phase 2
Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00420732 is a Phase 2 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 6 participants.
The verdict
NCT00420732, a Phase 2 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.
Interventions
- BIOLOGICAL HyperAcute-Lung Cancer Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420732
The ClinicalTrials.gov registry entry for NCT00420732 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HyperAcute-Lung Cancer Vaccine is the first listed.
NCT00420732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420732 about?
NCT00420732 is a clinical study titled "Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer". To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.
What is the current status of trial NCT00420732?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00420732?
The interventions under investigation include: HyperAcute-Lung Cancer Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00420732?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.